iOncology.ai: Indian AI Cancer Platform Spotlighted at BRICS Summit
iOncology.ai, an AI cancer care platform from India, gains international attention at the BRICS Summit, highlighting its potential in transforming cancer treatment.
An Indian artificial intelligence platform, iOncology.ai, is gaining international recognition for its innovative approach to cancer care. Developed collaboratively by the All India Institute of Medical Sciences (AIIMS) in New Delhi and the Centre for Development of Advanced Computing (C-DAC) in Pune, the platform was prominently featured in a special issue of The BRICS Health Journal during the recent BRICS Summit held on September 12-13.
AIIMS and C-DAC Lead the Innovation
Supported by the Ministry of Electronics and Information Technology, iOncology.ai is designed to integrate cancer-related clinical data to enhance early detection, risk stratification, treatment planning, and patient data management. The platform aims to bolster cancer care by leveraging artificial intelligence to improve screening, diagnosis, and access to specialized care, especially in resource-limited settings.
Dr. Ashok Sharma, a key contributor to the platform's development, highlighted the opportunity for India to bridge cancer-care disparities across the Global South through locally developed innovations like iOncology.ai. The platform is part of a broader effort to strengthen cancer prevention and treatment through evidence-based, interoperable solutions tailored to the needs of emerging economies.
Global Spotlight on Indian Innovation
The review titled "Transforming cancer care in emerging economies: India’s AI innovation," authored by Ashok Sharma and his team, underscores the potential impact of AI on cancer care within BRICS nations. With these countries accounting for over 40% of the global population and reporting about 9 million new cancer cases annually, the need for improved cancer care is critical.
The platform is currently in the pilot stage of clinical validation and implementation evaluation. Although it has not yet been clinically validated, the ongoing research aims to assess its diagnostic accuracy and clinical utility. Prospective multicentre validation is necessary before it can be widely adopted in clinical settings.
Future Prospects and Challenges
iOncology.ai is poised to become a significant component of India's expanding cancer-control infrastructure, which includes population screening and tertiary care. The platform utilizes curated Indian clinical, radiological, and histopathological datasets, with plans to incorporate genetic data and integrate with electronic health record systems.
Despite its promising potential, the platform's effectiveness and clinical utility are yet to be established through peer-reviewed evidence. The developers are optimistic that further validation will pave the way for its integration into clinical practice, ultimately leading to smarter and more equitable cancer care, especially in developing regions.